Claims for Patent: 6,428,785

Summary for Patent: 6,428,785

Title:	Method and composition for treating prostate cancer
Abstract:	A method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase. In one embodiment, a method of treating prostate cancer in a living mammal includes local administration of a composition that includes a therapeutically effective concentration of collagenase and at least one of a glycosidase, a protease, a nuclease, a lipase, an esterase, a plasminogen activator, a streptokinase, and combinations thereof. Preferably a glycosidase, such as, for example, hyaluronidase, is administered. Compositions used in methods for treating prostate cancer can also include or be administered with calcium ions, a nonionic surfactant, such as, for example, Triton.RTM. X-100, and an antibiotic, such as, for example, gentamicin. Another method of treating prostate cancer in a living mammal includes activating PSA in vivo by, for example, locally administering calcium ions.
Inventor(s):	Gokcen; Muharrem (Minneapolis, MN)
Assignee:	Immunolytics Inc. (Minneapolis, MN)
Application Number:	09/428,375
Patent Claims:	1. A method of treating localized prostate cancer in a mammal comprising intraprostatic administration of a composition comprising a therapeutically effective concentration of collagenase, hyaluronidase, CaCl.sub.2, a nonionic surfactant, an antibiotic, and a pharmaceutically acceptable aqueous carrier having a physiologic pH. 2. The method of claim 1, wherein the composition comprises collagenase at a concentration of about 250 to 250,000 U/ml and hyaluronidase at a concentration of about 160 to 160,000 U/ml. 3. The method of claim 2, wherein the composition comprises hyaluronidase at a concentration of about 1,600 to 16,000 U/ml. 4. The method of claim 1, wherein the nonionic surfactant comprises an ethylene oxide ester of a C.sub.10 -C.sub.20 fatty acid, an ethylene oxide ester of a C.sub.8 -C.sub.22 alkyl alcohol, or a combination thereof. 5. The method of claim 1, wherein the nonionic surfactant comprises alkylenylpolyoxexezlene. 6. The method of claim 1, wherein the antibiotic comprises gentamicin. 7. The method of claim 1, wherein the intraprostatic administration comprises intralesional injection. 8. The method of claim 1, wherein the intraprostatic administration comprises transurethral injection. 9. The method of claim 1, wherein the intraprostatic administration comprises transurethral injection, transrectal injection, or transperineal injection. 10. The method of claim 1, comprising administering a single injection of about 1 to 50 ml. 11. The method of claim 1, comprising administering a single injection of about 1 to 5 ml. 12. The method of claim 1, comprising administering a depot formulation. 13. The method of claim 1, comprising administering a slow release implant, a microencapsulated composition, or a conjugate with a biodegradable polymer, or conjugate with a prostate-specific immunoglobulin.

Details for Patent 6,428,785

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2039-02-26
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2039-02-26
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2039-02-26
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2039-02-26